1. 北京大学第三医院, a. 药剂科, b. 药物临床试验机构, 北京 100191; 2. 北京大学医学部药事管理与临床药学系, 北京 100191; 3. 北京大学治疗药物监测与临床毒理中心, 北京 100191
Therapeutic Drug Monitoring and Individualized Medication of Ribavirin
TAN Zhi-yuan1a,2, YU Zhi-heng1b, WU Zi-yang1a,2, LIU Wei1a,3, YANG Li1a,3, ZHAO Rong-sheng1a,3*
1a. Pharmacy Department, 1b. Clinical Trail Center, Peking University Third Hospital, Beijing 100191, China; 2. Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China; 3. Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University, Beijing 100191, China
Abstract：Ribavirin is a widely used nucleoside antiviral drug. During the epidemic of coronavirus disease 2019 (COVID-19), ribavirin was recommended for empirical treatment in the Clinical Management of Human Infection with COVID-19 (trial guidance v6). However, due to the large inter-individual variations in dose-response relationship, and extremely long terminal half time, it is necessary to perform therapeutic drug monitoring and individualized dose adjustment for ribavirin in special populations. In this article, the pharmacokinetics and therapeutic drug monitoring of ribavirin in different populations are reviewed in order to provide reference for clinical rational use and individualized medication of ribavirin for treatment of COVID-19.
WU F, ZHAO S, YU B, et al. A new coronavirus associated with human respiratory disease in China . Nature, 2020,579(7798):265-269.
[2]
KI M, NCO V T. Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Republic of Korea . Epidemiol Health, 2020,42:e2020007.
[3]
SHIGEMURA J, URSANO R J, MORGANSTEIN J C, et al. Public responses to the novel 2019 coronavirus (2019-nCoV) in Japan:mental health consequences and target populations . Psychiatry Clin Neurosci,2020,74(4):281-282.
[4]
GENERAL OFFICE OF THE NATIONAL HEALTH COMMISSION. Diagnosis and treatment of novel coronavirus pneumonia (trial version 5) . National Health Office Medical Letter, 2020 (2020-02-05). http://www.nhc.gov.cn/xcs/zhengcwj/202002/3b09b894ac9b4204a79db5b8912d4440.shtml.
[5]
GENERAL OFFICE OF THE NATIONAL HEALTH COMMISSION. Diagnosis and treatment of novel coronavirus pneumonia (revised trial version 5) . National Health Office Medical Letter ,2020 (2020-02-08). http://www.nhc.gov.cn/xcs/zhengcwj/202002/d4b895337e19445f8d728fcaf1e3e13a.shtml.
[6]
GENERAL OFFICE OF THE NATIONAL HEALTH COMMISSION. Diagnosis and treatment of novel coronavirus pneumonia (trial version 7) . National Health Office Medical Letter, 2020 (2020-03-03). http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[7]
KOREN G. Ribavirin in the treatment of SARA: a new trick for an old drug . CMAJ, 2003, 168(10):1289-1292.
[8]
HIRSCH H H, RODRIGO M, WARD K N, et al. Fourth European conference on infections in leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus . Clin Infect Dis, 2012, 56(2):258-266.
[9]
DIGNAN F L, CLARK A, AITKEN C, et al. BCSH/BSBMT/UK clinical virology network guideline:diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation . Br J Haematol, 173(3):380-393. PANEL A I H G. Hepatitis C guidance:AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus . Hepatology, 2015, 62(3):932-954. DONG H H, GAO Z Y. Determination of ribavirin and analysis of pharmacokinetics in human body . Guide China Med(中国医药指南), 2014, 12(17):87-88. LAFEUILLADE A, HITTINGER G, CHADAPAUD S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection . Lancet, 2001, 357(9252):280-281. LOUSTAUD-RATTI V, DEBETTE-GRATIEN M, JACQUES J. Ribavirin: past, present and future . World J Hepatol, 2016, 8(2):123-130. PRESTON S L, DRUSANO G L, GLUE P, et al. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology . Antimicrob Agents Chemother, 1999, 43(10):2451-2456. BUTT A A, UMBLEJA T, ANDERSEN J W, et al. The incidence, predictors and management of anaemia and its association with virological response in HCV/HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin . Aliment Pharmacol Ther, 2011, 33(11):1234-1244. GHANY M G, STRADER D B, THOMAS D L, et al. Diagnosis, management, and treatment of hepatitis C: an update . Hepatology, 2004, 39(4):1147-1171. FDA. Copegus-FDA prescribing information, side effects and uses.USA, 2011 (2019-10-22). https://www.drugs.com/pro/copegus.html. BRENNAN B J, WANG K, BLOTNER S, et al. Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment . Antimicrob Agents Chemother, 2013, 57(12):6097-6105. GLUE P, SCHENKER S, GUPTA S, et al. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease . Brit J Clin Pharmacol, 2000, 49(5):417-421. GONZLEZ-PERALTA R P, KELLY D A, HABER B, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics . Hepatology, 2005, 42(5):1010-1018. HALL C B, WALSH E E, HRUSKA J F, et al. Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults . JAMA, 1983, 249(19):2666-2670. RODRIGUEZ W J, PARROTT R H. Ribavirin aerosol treatment of serious respiratory syncytial virus infection in infants . Infect Dis Clin North Am, 1987, 1(2):425-439. DAVID, BERNSTEIN, RAKESH, et al. Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection . Hepat Med, 2019, 13(11):35-40. LINDAHL K, SCHVARCZ R, BRUCHFELD A, et al. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia . J Viral Hepat, 2004, 11(1):84-87. BRUCHFELD A, LINDAHL K, SCHVARCZ R, et al. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis . Ther Drug Monit, 2002, 24(6):701-708. LINDAHL K, HRNFELD E, STHLE L, et al. High-dose ribavirin enhances early virological response in hepatitis C genotype 1-infected patients . Ther Drug Monit, 2015, 37(6):745-750. MAYNARD M, PRADAT P, GAGNIEU M C, et al. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C genotype 1 patients . Antivir Ther, 2008, 13(4):607-611. LOUSTAUD-RATTI V, ALAIN S, ROUSSEAU A, et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C . Hepatology, 2008, 47(5):1453-1461. MAEDA Y, KIRIBAYASHI Y, MORIYA T, et al. Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C . Ther Drug Monit, 2004, 26(1):9-15. ARASE Y, IKEDA K, TSUBOTA A, et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C . Intervirology, 2005, 48(2-3):138-144. DONNERER J, GRAHOVAC M, STELZL E, et al. Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy . Pharmacology, 2006, 76(3):136-140. INOUE Y, HOMMA M, MATSUZAKI Y, et al. Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy . Hepatol Res, 2006, 34(1):23-27. WADE J R, ERIC S, FRANK D, et al. Pharmacokinetics of ribavirin in patients with hepatitis C virus . Br J Clin Pharmacol, 2006, 62(6):710-714.
2020, Vol. 55 
